Literature DB >> 23180232

Reappraisal of birdshot retinochoroiditis (BRC): a global approach.

Marina Papadia1, Carl P Herbort.   

Abstract

BACKGROUND: This study aimed to readjust the appraisal of birdshot retinochoroiditis (BRC) in light of a global approach, including the full array of investigational procedures. PATIENTS AND METHODS: This retrospective study reviewed charts of BRC cases treated in the uveitis clinic of our center between 1995 and 2011. We identified 25 patients with BRC; of these, 19 had sufficient data for inclusion in the study. Patients were examined with a standard clinical approach for inflammatory disorders, including dual fluorescence angiography with fluorescein and indocyanine green, perimetry, and laser flare photometry, both at presentation and during follow-up. Spectral optical coherence tomography (OCT) was performed when available. Disease characteristics and evolutionary patterns were reported.
RESULTS: Human leucocyte antigen was positive for the A29 allele in all patients. The mean age at presentation was 49.6 ± 10.0 years, the mean diagnostic delay was 21.5 ± 18 months, and the mean follow-up was 85 ± 60 months. Out of 19 patients, three presented with mutton-fat keratic precipitates (KPs), three had no depigmented lesions at presentation, and eight did not fulfill the recommended criterion of three depigmented peripapillar lesions. Cystoid macular edema (CMO) at entry was present in 8/19 cases. Perimetric anomalies were noted in all patients at presentation. In 92 % of cases, fluorescein findings included disc hyperfluorescence, retinal vasculitis of large vessels, and leakage from medium-sized and small vessels. In all patients, a (pseudo)-delay was noted in the arterio-venous circulation time (mean venous dye appearance = 42.1 ± 13.1 s), which reflected massive capillary leakage. At presentation, all patients exhibited indocyanine green angiographic signs, including hypofluorescent dark dots, vessel fuzziness, and areas of diffuse late hyperfluorescence. This allowed early diagnosis in 3/19 patients (16 %) without birdshot fundus lesions at presentation.
CONCLUSIONS: BRC is a granulomatous uveitis, and mutton-fat KPs do not exclude the disease. When BRC is suspected, indocyanine green angiography is crucial to allow early diagnosis and to monitor the evolution of choroiditis. Perimetry is an obligate investigation for diagnosis and follow-up. CMO is less frequent than stated earlier. Scores of fluorescein and indocyanine green angiographic signs indicated that choroiditis responded readily to therapy, but retinitis was relatively resistant to therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180232     DOI: 10.1007/s00417-012-2201-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  28 in total

Review 1.  [Indocyanine green angiography in ocular inflammatory diseases: principles, schematic interpretation, semiology and clinical value].

Authors:  C P Herbort; B Bodaghi; P Lehoang
Journal:  J Fr Ophtalmol       Date:  2001-04       Impact factor: 0.818

2.  Choroidal lesions preceding symptom onset in birdshot chorioretinopathy.

Authors:  Lyndell Lim; Alex Harper; Robyn Guymer
Journal:  Arch Ophthalmol       Date:  2006-07

3.  Prolonged retinal arterio-venous circulation time by fluorescein but not by indocyanine green angiography in birdshot chorioretinopathy.

Authors:  Y Guex-Crosier; C P Herbort
Journal:  Ocul Immunol Inflamm       Date:  1997-09       Impact factor: 3.070

4.  Schematic interpretation of indocyanine green angiography in posterior uveitis using a standard angiographic protocol.

Authors:  C P Herbort; P LeHoang; Y Guex-Crosier
Journal:  Ophthalmology       Date:  1998-03       Impact factor: 12.079

Review 5.  Birdshot chorioretinopathy.

Authors:  Kayur H Shah; Ralph D Levinson; Fei Yu; Raquel Goldhardt; Lynn K Gordon; Christine R Gonzales; John R Heckenlively; Peter J Kappel; Gary N Holland
Journal:  Surv Ophthalmol       Date:  2005 Nov-Dec       Impact factor: 6.048

6.  Birdshot retinochoroidopathy: ocular complications and visual impairment.

Authors:  Jennifer E Thorne; Douglas A Jabs; George B Peters; David Hair; James P Dunn; John H Kempen
Journal:  Am J Ophthalmol       Date:  2005-07       Impact factor: 5.258

7.  Indocyanine green angiography in birdshot chorioretinopathy.

Authors:  C Fardeau; C P Herbort; N Kullmann; G Quentel; P LeHoang
Journal:  Ophthalmology       Date:  1999-10       Impact factor: 12.079

8.  Loss of visual field among patients with birdshot chorioretinopathy.

Authors:  Jennifer E Thorne; Douglas A Jabs; Sanjay R Kedhar; George B Peters; James P Dunn
Journal:  Am J Ophthalmol       Date:  2007-11-12       Impact factor: 5.258

9.  Choroidal circulatory disturbance in ocular sarcoidosis without the appearance of retinal lesions or loss of visual function.

Authors:  Shigeki Machida; Michiko Tanaka; Kenichi Murai; Tomomi Takahashi; Yutaka Tazawa
Journal:  Jpn J Ophthalmol       Date:  2004 Jul-Aug       Impact factor: 2.447

10.  Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease.

Authors:  Tatsushi Kawaguchi; Shintaro Horie; Nadia Bouchenaki; Kyoko Ohno-Matsui; Manabu Mochizuki; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2009-01-17       Impact factor: 2.031

View more
  13 in total

Review 1.  New concepts in the appraisal and management of birdshot retinochoroiditis, a global perspective.

Authors:  Marina Papadia; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2015-02-14       Impact factor: 2.031

2.  Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt-Koyanagi-Harada disease.

Authors:  Ozlem Balci; Bruno Jeannin; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2017-03-15       Impact factor: 2.031

3.  Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy.

Authors:  Laura R Steeples; Paul Spry; Richard W J Lee; Ester Carreño
Journal:  Int Ophthalmol       Date:  2017-06-12       Impact factor: 2.031

4.  Early and sustained treatment modifies the phenotype of birdshot retinochoroiditis.

Authors:  Pascal B Knecht; Marina Papadia; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2013-10-01       Impact factor: 2.031

Review 5.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

6.  Birdshot chorioretinopathy in a male patient with facioscapulohumeral muscular dystrophy.

Authors:  Evangelia Papavasileiou; Ann-Marie Lobo
Journal:  J Ophthalmic Inflamm Infect       Date:  2015-03-12

Review 7.  Gender differences in birdshot chorioretinopathy and the white dot syndromes: do they exist?

Authors:  Lisa J Faia
Journal:  J Ophthalmol       Date:  2014-02-09       Impact factor: 1.909

8.  Why birdshot retinochoroiditis should rather be called 'HLA-A29 uveitis'?

Authors:  Carl P Herbort; Carlos Pavésio; Phuc LeHoang; Bahram Bodaghi; Christine Fardeau; Philippe Kestelyn; Piergiorgio Neri; Marina Papadia
Journal:  Br J Ophthalmol       Date:  2017-03-17       Impact factor: 4.638

Review 9.  Classification of Non-Infectious and/or Immune Mediated Choroiditis: A Brief Overview of the Essentials.

Authors:  Carl P Herbort; Alessandro Mantovani; Ilknur Tugal-Tutkun; Ioannis Papasavvas
Journal:  Diagnostics (Basel)       Date:  2021-05-24

Review 10.  Birdshot uveitis: current and emerging treatment options.

Authors:  Victor Menezo; Simon Rj Taylor
Journal:  Clin Ophthalmol       Date:  2013-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.